P4‐351: Evaluation of TAU Burden in a Cross‐Sectional Cohort of Alzheimer’S Disease Subjects Using [<sup>18</sup>F]GTP1 (GENENTECH TAU PROBE 1)
Sandra Sanabria Bohórquez, Geoffrey A. Kerchner(Roche (Switzerland)), Gilles Tamagnan(Chapel Haven Schleifer Center), John Seibyl(Elucid Bioimaging), Robby M. Weimer(Sunesis (United States)), Danna Jennings, Gai Ayalon, Alex de Crespigny(Acentech (United States)), Jan Mařı́k(UC Davis Comprehensive Cancer Center), Kenneth Marek(University of Pennsylvania), David Alagille(Chapel Haven Schleifer Center), Thomas Bengtsson(WeMind), Olivier Barret(Invicro (United States))
Cited by 14
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes
|Proceedings of the National Academy of Sciences|2010|666